Coloplast reported Q3 19 numbers in line with consensus as well as our estimates. Sales were up 8% on an organic basis, driven by broad-based growth across segments, while the EBIT margin came in at 31%. Management re-iterated its FY 2019 expectations: organic growth of ~8% (reported growth of ~9%) and an EBIT margin of 30-31% at CER (~31% reported). Following the largely in line performance, we do not expect any major change in our estimates.
22 Aug 2019
Urology leads in Q3
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Urology leads in Q3
Coloplast A/S Class B (COLO:WBO) | 0 0 1.7% | Mkt Cap: 103,237m
- Published:
22 Aug 2019 -
Author:
Virendra Chauhan -
Pages:
3
Coloplast reported Q3 19 numbers in line with consensus as well as our estimates. Sales were up 8% on an organic basis, driven by broad-based growth across segments, while the EBIT margin came in at 31%. Management re-iterated its FY 2019 expectations: organic growth of ~8% (reported growth of ~9%) and an EBIT margin of 30-31% at CER (~31% reported). Following the largely in line performance, we do not expect any major change in our estimates.